This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.

Ticker(s): MRK

Who's the expert?

Institution: Upstate Medical University

  • Professor of Internal Medicine, Surgery, and Pediatrics; Medical Director of Dialysis at Norton College of Medicine at Upstate Medical University.
  • Sees 300 patients a month with renal disease, with 100 being on dialysis (ESRD).
  • Clinical Research includes projects exploring cardiovascular disease in patients with chronic kidney disease and development of a non-invasive blood analyte sensing device.

Interview Questions

Please describe your background and practice setting

Added By: ben_admin

How many patients with renal disease do you treat monthly?

Added By: ben_admin

How many of your patients will experience major thrombotic cardiovascular events?

Added By: ben_admin

What current medications do you use to prevent major thrombotic cardiovascular events?

Added By: ben_admin

Are you familiar with Factor 11a inhibitors? What potential do they bring to limiting bleeding in patients compared to factor 10a inhibitors?

Added By: ben_admin

What were your overall thoughts about Merck's MK-2060 study and its potential? Do most ESRD patients tend to have underlying conditions like diabetes, high blood pressure, atrial fibrillation, and cardiovascular disease that increase their risk of blood clots? Is this a large unmet need?

Added By: ben_admin

Are you familiar with Bayer and Ionis antisense-based Factor XI inhibitor, fesomersen?

Added By: ben_admin

Do a large percentage of your patients experience increased bleeding due to other anticoagulation medications? What % of decrease in clotting factors meets your threshold for positivity?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.